Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT06148181 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.

NCT ID: NCT06147921 Not yet recruiting - Healthy Volunteers Clinical Trials

Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants

Start date: December 15, 2023
Phase: Phase 1
Study type: Interventional

Verasone™ is an aqueous suspension of the combination of two marketed drugs to be dosed by sinonasal irrigation in the treatment of Chronic Rhinosinusitis (CRS). This Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of Verasone versus placebo in healthy normal participants and will evaluate the PK profiles of the Verasone active components administered individually vs in combination.

NCT ID: NCT06144684 Recruiting - Healthy Volunteers Clinical Trials

A First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a single center, double-blind, randomized, placebo-controlled, single ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men. It is planned to enroll 4 cohorts of 8 subjects (Regimens A, B, C and D), with 2 additional optional cohorts of 8 subjects (Regimens E and F). Within each cohort, subjects will be randomized in a ratio of 6 active to 2 placebo. The primary objective is to assess the safety. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate pharmacodynamic effects.

NCT ID: NCT06143319 Completed - Healthy Volunteers Clinical Trials

Structural White and Gray Matter Correlates of Impaired Muscle Control and Deficient Pain Processing

B~Maps
Start date: October 1, 2015
Phase:
Study type: Observational

Although the cause of persistent non-specific low back pain (LBP) remains unknown, structural and functional alterations of the brain, alterations in the lumbar muscles and dysfunction of the central nervous system have been proposed as underlying mechanisms. In this case-control study, 1) brain structure/function, 2) lumbar muscle function and 3) central pain processing are compared across four groups: 1) healthy participants, 2) recurrent LBP (both during pain flare and during pain remission), 3) chronic LBP and 4) fibromyalgia. According to previous research, healthy participants and fibromyalgia patients are two extremes of a "musculoskeletal pain continuum". Healthy participants representing one extreme of the continuum with no pain and fibromyalgia representing the other extreme of the continuum with chronic widespread pain. It is thought that different LBP populations (i.e. (sub)acute, recurrent, chronic LBP) float between the aforementioned extremes. Past studies already highlighted the need for studies comparing the pathophysiological mechanisms for different pain syndromes to identify common underlying mechanisms across pain syndromes. For this reason, the goal of the current study is to compare alterations in brain structure/function, alterations in lumbar muscle function and alterations in central pain processing across the aforementioned "musculoskeletal pain continuum". It is hypothesized that longer duration of pain (recurrent vs chronic) and the extensiveness of the pain (one location vs widespread pain) are associated with more pronounced alterations in 1) brain structure/function, 2) lumbar muscle function and 3) central pain processing.

NCT ID: NCT06141889 Not yet recruiting - Clinical trials for Healthy Volunteer Study

Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-dose, open-label, randomized crossover study to evaluate the PK of azelaprag in older adult healthy volunteers.

NCT ID: NCT06139055 Recruiting - Healthy Volunteers Clinical Trials

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

NCT ID: NCT06137482 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Start date: December 5, 2023
Phase: Phase 1
Study type: Interventional

This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults. The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug - How much study drug is present in the blood of study participants at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

NCT ID: NCT06135181 Completed - Healthy Volunteers Clinical Trials

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Start date: August 26, 2020
Phase: Phase 1
Study type: Interventional

The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Chinese healthy male participants: - the safety of BAY1747846 when given at increasing single doses - the level of BAY1747846 in the blood over time when given at increasing single doses. To answer the first question, the researchers compared the number and severity of medical problems the Chinese participants had after receiving BAY1747846 at increasing doses and placebo respectively. Doctors kept tracking of all medical problems that happened in the study, even if they did not think they might be related to the study treatments. To answer the second question, the researchers determined: - the (average) total level of BAY1747846 in the blood, also called AUC - the (average) highest level of BAY1747846 in the blood, also called Cmax - how BAY1747846 is removed from the blood, also called clearance (CL).

NCT ID: NCT06134648 Recruiting - Healthy Volunteers Clinical Trials

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Start date: November 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.

NCT ID: NCT06133478 Not yet recruiting - Healthy Volunteers Clinical Trials

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Start date: November 27, 2023
Phase: Phase 1
Study type: Interventional

This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001